Genetic Bone Diseases
Jul 06, 2017
Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO
Stada’s €5.3B buyout Sinks, brings in new CEO and CFO After failing to win the shareholder support needed to complete a €5.32 billion buyout, Stada is changing key executives. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helmut Kraft following a board meeting on Tuesday and quickly appoi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
